Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing

Lou Whiteman

๐Ÿ‘ค Speaker
See mentions of this person in podcasts
2759 total appearances

Appearances Over Time

Podcast Appearances

Motley Fool Money
Nobody Told Us This Was M&A Week

It gives it a major efficiency advantage over its competitors.

Motley Fool Money
Nobody Told Us This Was M&A Week

On the other hand, Restaurant Depot, it's a network of in-person wholesale restaurant supply warehouses.

Motley Fool Money
Nobody Told Us This Was M&A Week

Think of it as like a Costco or a Sam's Club, but specifically for restaurants.

Motley Fool Money
Nobody Told Us This Was M&A Week

It's carved out a very nice niche among restaurant owners who value flexibility in pricing over the convenience of the national distributor, Cisco.

Motley Fool Money
Nobody Told Us This Was M&A Week

There have been a few decent examples of deals like this that have worked.

Motley Fool Money
Nobody Told Us This Was M&A Week

Performance Food Group, getting back to the Cisco situation, is one that looks really interesting.

Motley Fool Money
Nobody Told Us This Was M&A Week

Ticker symbol is PFGC.

Motley Fool Money
Nobody Told Us This Was M&A Week

Between 2019 and 2023, it acquired three of its major competitors, including Cheney Brothers, which is a big Cisco competitor.

Motley Fool Money
Nobody Told Us This Was M&A Week

A major reason was to add new consumer segments, which is one of the reasons Cisco is acquiring Restaurant Warehouse.

Motley Fool Money
Nobody Told Us This Was M&A Week

The stock is up 160% since the start of 2019.

Motley Fool Money
Nobody Told Us This Was M&A Week

I'd call that a pretty solid example and a pretty close parallel.

Motley Fool Money
Nobody Told Us This Was M&A Week

But I completely see your point.

Motley Fool Money
Nobody Told Us This Was M&A Week

There is a lot that can go wrong with these types of acquisitions, especially when a company like Cisco is taking on $21 billion of new debt to make it happen.

Motley Fool Money
Nobody Told Us This Was M&A Week

Yeah, that's a really good question.

Motley Fool Money
Nobody Told Us This Was M&A Week

As you mentioned, they're a clinical-stage pharmaceutical.

Motley Fool Money
Nobody Told Us This Was M&A Week

They develop treatments for rare diseases.

Motley Fool Money
Nobody Told Us This Was M&A Week

It's not just narcolepsy.

Motley Fool Money
Nobody Told Us This Was M&A Week

They have some other things in the pipeline, but that's their most promising candidate.

Motley Fool Money
Nobody Told Us This Was M&A Week

They have a product that's in later-stage trials.

Motley Fool Money
Nobody Told Us This Was M&A Week

Phase II trial data was very promising.